The $80,000 price tag for Eli Lilly and Co. and Bristol-Myers Squibb's cancer drug Erbitux is too high considering it prolongs patients' survival only about 1.2 months more when combined with other treatments than chemotherapy alone, two U.S. scientists said in a commentary in the Journal of the National Cancer Institute. Bristol-Myers estimated that Erbitux costs about $10,000 a month, a company spokesman said, and the product is not meant for all cancer patients.

Full Story:

Related Summaries